Clearmind Medicine Inc. (Nasdaq:CMND) experienced a 3.8% rise in premarket trading on Tuesday after receiving Institutional Review Board approval from Johns Hopkins Medicine to proceed with later stages of its Phase I/II trial of CMND-100.
The IRB approval authorizes Clearmind to move forward with Parts B and C of a multicenter study that will assess CMND-100 in both healthy volunteers and people diagnosed with Alcohol Use Disorder. These upcoming portions of the trial are designed to examine single and multiple dose tolerability, the safety profile, and pharmacokinetic behavior of the compound.
CMND-100 is described by the company as a non-hallucinogenic, MEAI-based compound intended to treat Alcohol Use Disorder. The development program at Johns Hopkins follows earlier stages of the same trial that were completed at that institution.
"This IRB approval represents another important step forward in our clinical development program for CMND-100," said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.
Clearmind is a clinical-stage biotechnology company focused on advancing non-hallucinogenic, neuroplastogen-derived therapeutics aimed at underserved health problems. The company reports an intellectual property portfolio that includes nineteen patent families and 31 granted patents.
The authorized progression into Parts B and C will enable the sponsor to gather data on tolerability and pharmacokinetics across single and repeated dosing regimens in the targeted populations noted above. The company framed the development as a continuation of work already initiated at Johns Hopkins, a center involved in the trial’s earlier phases.
Investors responded in premarket activity to the institutional review board decision, producing the reported intraday gain for the company’s shares. The approval clears the way for continued clinical work but does not itself report outcomes from the parts of the study now scheduled to proceed.
Details provided by the company emphasize the non-hallucinogenic profile of the candidate and its MEAI-based chemistry as central attributes of CMND-100, while the firm’s broader strategy highlights the development of neuroplastogen-derived medicines for clinical needs that the company characterizes as underserved.
Summary
Clearmind secured IRB approval from Johns Hopkins Medicine to advance Parts B and C of its Phase I/II CMND-100 trial, prompting a 3.8% premarket share increase. The trial will evaluate tolerability, safety, and pharmacokinetics in healthy volunteers and patients with Alcohol Use Disorder. CMND-100 is a non-hallucinogenic, MEAI-based compound, and the company maintains a portfolio of 19 patent families with 31 granted patents.